Shareholder Alert: Ademi LLP investigates whether CymaBay Therapeutics, Inc. has obtained a Fair Price in its transaction with Gilead

Provided By PR Newswire

Last update: Feb 12, 2024

MILWAUKEE, Feb. 12, 2024 /PRNewswire/ -- Ademi LLP is investigating CymaBay (Nasdaq: CBAY) for possible breaches of fiduciary duty and other violations of law in its transaction with Gilead.